Clinical trials: Sitagliptin
Type 2 Diabetes Mellitus
Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone
This trial is to evaluate the efficacy and safety of CWP-0403 compared to Sitagliptin by proving non-inferiority in patients with type 2 Diabetes Mellitus insufficiently controlled with metformin alone.
- Trial name
- CWP-DIANA-302 (NCT01529541)
- Testing
- Anagliptin, Sitagliptin
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- JW Pharmaceutical
Type 2 Diabetes Mellitus
Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)
This is a study to assess the safety and efficacy of the addition of ipragliflozin once daily in Japanese participants with Type 2 diabetes mellitus (T2DM) who have inadequate glycemic control on sitagliptin, diet, and exercise…
- Trial name
- NCT02577003
- Testing
- Ipragliflozin, Sitagliptin
- Volunteers
- 143 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus, Cardiovascular Disease
Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)
There are recent advances in therapies for the treatment of Type 2 Diabetes Mellitus (T2DM) which include the GLP1 analogues and the DPP IV inhibitors.
- Trial name
- LYDIA (NCT02043054)
- Testing
- Liraglutide, Sitagliptin
- Where
- United Kingdom
- Volunteers
- 90 people
- Sponsor
- University of Leicester
Type 2 Diabetes Mellitus
A Study to Investigate the Glucose Lowering Effects of Dextromethorphan Alone or in Combination With Sitagliptin in Subjects With Type 2 Diabetes Mellitus (T2DM) After an Oral Glucose Tolerance Test
The study has a randomized, double-blind, placebo-controlled, double dummy and eight-way cross-over design. Males with T2DM on a stable metformin monotherapy will be screened for participation in the study.
- Trial name
- DXM2 (NCT01936025)
- Testing
- Dextromethorphan, Sitagliptin
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Type 2 Diabetes Mellitus
A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)
This study will evaluate the effect of a single dose of sitagliptin on glucose dependent insulin secretion using a meal tolerance test (MTT) during a hyperglycemic clamp (HCG) procedure.
- Trial name
- NCT00888238
- Testing
- sitagliptin
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Effect of Sitagliptin on Endothelial Progenitor Cells
Endothelial progenitor cells (EPCs) are involved in cardiovascular homeostasis, through angiogenesis and endothelial healing. Diabetic patients have a high risk of cardiovascular events and low levels of circulating EPCs.
- Trial name
- NCT00968006
- Testing
- Sitagliptin
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- University of Padova
Type 2 Diabetes Mellitus
Sitagliptin Cardiovascular Outcomes Study (MK-0431-082)
This is a clinical trial designed to assess the cardiovascular outcome of long-term treatment with sitagliptin used as part of usual care compared to usual care without sitagliptin in participants with type 2 diabetes mellitus…
- Trial name
- TECOS (NCT00790205)
- Testing
- Sitagliptin
- Volunteers
- 14,671 people
- Sponsor
- Merck Sharp & Dohme LLC
Type II Diabetes
Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers
The primary objective of this study is to compare the rate of healing as well as percent of wounds healed in Type II diabetic patients with chronic foot ulcerations receiving sitagliptin versus placebo.
- Trial name
- NCT02015910
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Georgetown University
Type 2 Diabetes Mellitus
Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)
This study will assess the efficacy and safety of initial treatment with sitagliptin and metformin in patients with type 2 diabetes mellitus in China.
- Trial name
- NCT01076088
- Testing
- Sitagliptin 50 mg, Metformin 500 mg, Sitagliptin 100 mg
- Volunteers
- 744 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)
The purpose of this investigational study is to determine the safety and effectiveness of an investigational drug in patients with type 2 diabetes mellitus (a specific type of diabetes).
- Trial name
- NCT00094770
- Testing
- sitagliptin (MK0431), Comparator: glipizide
- Volunteers
- 1,172 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Long Term Effects of DPP-IV Inhibitor Treatment in Patients With Type 2 Diabetes
We wish to evaluate the effect of long term treatment with a DPP-IV inhibitor on the function of the incretin hormones Hypothesis We hypothesize that that a gradual improvement in metabolic control induced by DPP-IV inhibitor…
- Trial name
- NCT00411411
- Testing
- Januvia
- Where
- Denmark
- Volunteers
- 49 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Heart Failure With Preserved Ejection Fraction, Chronic Heart Failure
Emulation of the EMPEROR-Preserved Trial Using Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials.
- Conditions
- Heart Failure With Preserved Ejection Fraction, Chronic Heart Failure, Type 2 Diabetes Mellitus
- Trial name
- NCT07599293
- Testing
- Empagliflozin, Sitagliptin
- Where
- United States
- Volunteers
- 39,614 people
- Sponsor
- Brigham and Women's Hospital
Type 2 Diabetes Mellitus
A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)
The purpose of this study is to assess the effect of the addition of sitagliptin (administered as MK-0431A or MK-0431A XR) relative to the addition of placebo on glycated hemoglobin (A1C), and the safety and tolerability of the…
- Trial name
- NCT01760447
- Testing
- Sitagliptin plus metformin, Metformin, Sitagliptin plus metformin XR
- Volunteers
- 223 people
- Sponsor
- Merck Sharp & Dohme LLC
Myocardial Infarction, Unstable Angina Pectoris
Beta-cell Function in Glucose Abnormalities and Acute Myocardial Infarction
A three months, double-blind, randomised, parallel-group study evaluating the efficacy of sitagliptin (Januvia™) versus placebo on beta-cell function in patients with newly detected glucose abnormalities and acute myocardial…
- Conditions
- Myocardial Infarction, Unstable Angina Pectoris, Diabetes Mellitus, Impaired Glucose Tolerance
- Trial name
- BEGAMI (NCT00627744)
- Testing
- Sitagliptin
- Where
- 2 sites in Sweden
- Volunteers
- 85 people
- Sponsor
- Karolinska Institutet
Type 2 Diabetes
TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.
The aim of this project is to identify subgroups of patients with type 2 diabetes that respond well or poorly to particular drugs based on particular clinical characteristics such as their weight or kidney function, to enable…
- Trial name
- TriMaster (NCT02653209)
- Testing
- Sitagliptin - DPP4i, Canagliflozin - SGLT2i, Pioglitazone - TZD
- Where
- United Kingdom
- Volunteers
- 525 people
- Sponsor
- Royal Devon and Exeter NHS Foundation Trust
Type II Diabetes
Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763
This study is a three part study to assess the safety and efficacy of LEZ763 on normal healthy volunteers and patients with Type 2 Diabetes.
- Trial name
- NCT01619332
- Testing
- Sitagliptin, LEZ763
- Where
- 6 sites in United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
Dietary Impacts on Glucose-lowering Effects of Sitagliptin in Type 2 Diabetes
In a prospective, randomized case-controlled study, the investigators hope to demonstrate a positive correlation of plasma levels of EPA and DHA as well as fish intake with the HbA1c-lowering effect of sitagliptin but not with…
- Trial name
- DIET (NCT02312063)
- Testing
- Sitagliptin, Glimepiride
- Where
- 2 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Kansai Electric Power Hospital
Type 2 Diabetes Mellitus
Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)
The purpose of this study is to assess the efficacy of omarigliptin 25 mg weekly (as monotherapy) compared with sitagliptin 50 mg daily and placebo, and the long term safety (up to 52 weeks) of omarigliptin 25 mg weekly.
- Trial name
- NCT01703221
- Testing
- Omarigliptin, Sitagliptin
- Volunteers
- 414 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Efficacy and Safety of Lobeglitazone Versus Sitagliptin
Efficacy and Safety of Lobeglitazone versus Sitagliptin in inadequately controlled by Metformin alone Type 2 Diabetes mellitus Patients with Metabolic syndrome.
- Trial name
- NCT02480465
- Testing
- Lobelitazone 0.5mg, Sitagliptin 100mg
- Where
- South Korea
- Volunteers
- 248 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Healthy Volunteers
Bioequivalence Study of Sitagliptin/Metformin Extended-Release Tablets in Healthy Subjects
The main purpose of this study is to compare the pharmacokinetics (how the body absorbs and clears the drug) and evaluate the bioequivalence of two formulations of sitagliptin/metformin hydrochloride extended-release tablets (50…
- Trial name
- NCT07679711
- Testing
- Sitagliptin / Metformin hydrochloride extended-release tablet (Test), Sitagliptin / Metformin hydrochloride extended-release tablet (Reference)
- Where
- China
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- The Affiliated Hospital of Qingdao University